Progressive Multifocal Leukoencephalopathy in a HIV-Negative Patient with Small Lymphocytic Leukemia following Treatment with RituximabChakraborty S.a · Tarantolo S.R.b · Treves J.c · Sambol D.d · Hauke R.J.b · Batra S.K.a, e, f
aDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, bNebraska Cancer Specialists, cMidwest Neurosurgery and Spine Specialists, dPhysicians of Internal Medicine, eDepartment of Pathology and Microbiology, and fEppley Institute for Cancer Research, University of Nebraska Medical Center, Omaha, Nebr., USA
Surinder K. Batra, PhD
Department of Biochemistry and Molecular BiologyEppley Institute for Research in Cancer and Allied DiseasesUniversity of Nebraska Medical Center
Omaha, NE 68198-5870 (USA)
Tel. +1 402 559 5455, E-Mail firstname.lastname@example.org
Ralph J. Hauke, MD Nebraska Cancer Specialists, P.C.
8303 Dodge Street, Suite 250
Omaha, NE 68127 (USA)
Tel. +1 402 354 8124, E-Mail email@example.com
Do you have an account?
We describe a case of progressive multifocal leukoencephalopathy (PML) caused by infection with the human polyomavirus JC virus in a patient with B-cell small lymphocytic leukemia who was treated with rituximab. The first symptoms of PML appeared immediately following the last of five cycles of rituximab, cyclophosphamide and pentostatin. Magnetic resonance imaging revealed changes consistent with PML, although JC virus DNA was not detected by polymerase chain reaction assay of the cerebrospinal fluid. A stereotactic biopsy of the brain showed histological changes consistent with PML, while electron microscopy revealed JC virus particles attached to the nuclei of astrocytes. The patient was treated supportively but died 53 days after the initial onset of symptoms.
© 2011 S. Karger AG, Basel
Article / Publication Details
Open Access License / Drug Dosage / DisclaimerOpen Access License: This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.